Prenetics Global Limited Class A Ordinary Share (PRE) is a publicly traded Healthcare sector company. As of May 20, 2026, PRE trades at $15.25 with a market cap of $247.19M and a P/E ratio of 0.00. PRE moved +4.28% today. Year to date, PRE is -7.38%; over the trailing twelve months it is +110.89%. Its 52-week range spans $3.09 to $23.63. Analyst consensus is buy with an average price target of $32.50. Rallies surfaces PRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Prenetics Raises 2026 IM8 Guidance to $210M, Adds Jay Shetty as Shareholder: Prenetics raised its 2026 IM8 revenue guidance to $190 million–$210 million after delivering $33.8 million in Q1 sales, a 6× year-over-year increase. It named Jay Shetty as global IM8 ambassador and shareholder, expanding its equity-aligned roster to drive brand reach across his 70-million-plus follower audience.
| Metric | Value |
|---|---|
| Price | $15.25 |
| Market Cap | $247.19M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.70% |
| 52-Week High | $23.63 |
| 52-Week Low | $3.09 |
| Volume | 64.78K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.39B |
| Net Income | $74.63M |
| Gross Margin | 14.89% |
2 analysts cover PRE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $32.50.